Idoia Gamez

Summary

Publications

  1. doi request reprint Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models
    Idoia Gamez
    Celtic Pharmaceutical Development Services America, Inc, 663 Fifth Ave, 7th Floor, New York, 10022 NY, USA
    Cancer Chemother Pharmacol 67:1415-22. 2011
  2. ncbi request reprint Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models
    Idoia Gamez
    Celtic Pharmaceutical Development Services America, Inc, New York, NY 10022, USA
    Anticancer Res 30:5037-42. 2010
  3. pmc Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas
    Maxim A Moroz
    Department of Neurology and Radiology, Sloan Kettering Institute Molecular Pharmacology and Chemistry Program, Inc, New York, NY 10065, USA
    Clin Cancer Res 17:3282-92. 2011

Collaborators

  • Stephen T Keir
  • Maxim A Moroz
  • Robert P Ryan
  • Tatiana Kochetkov
  • Howard Thaler
  • Ruimin Huang
  • Elisa de Stanchina
  • Weiji Shi
  • Ronald G Blasberg

Detail Information

Publications3

  1. doi request reprint Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models
    Idoia Gamez
    Celtic Pharmaceutical Development Services America, Inc, 663 Fifth Ave, 7th Floor, New York, 10022 NY, USA
    Cancer Chemother Pharmacol 67:1415-22. 2011
    ..We sought to investigate preclinically its potential as an antitumor agent against human solid tumors and to assess its ability to enhance the therapeutic activity of bevacizumab (BEV) in these same models...
  2. ncbi request reprint Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models
    Idoia Gamez
    Celtic Pharmaceutical Development Services America, Inc, New York, NY 10022, USA
    Anticancer Res 30:5037-42. 2010
    ..This study preclinically investigated its potential as an antitumor agent against human brain tumor xenografts...
  3. pmc Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas
    Maxim A Moroz
    Department of Neurology and Radiology, Sloan Kettering Institute Molecular Pharmacology and Chemistry Program, Inc, New York, NY 10065, USA
    Clin Cancer Res 17:3282-92. 2011
    ..Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide...